Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AX251
- Development stage
- Unknown
- Lead developer
- Anxo Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
AX251 is a long-acting injectable (LAI) formulation of cariprazine, an atypical antipsychotic, being developed by Anxo Pharmaceutical Co., Ltd. for the treatment of schizophrenia. Cariprazine, the active moiety, functions as a partial agonist at dopamine D3 and D2 receptors, with a notably high affinity for the D3 subtype, and as a partial agonist at serotonin 5-HT1A receptors. The LAI formulation is designed to improve treatment adherence and provide stable therapeutic drug levels over an extended period compared to daily oral administration. AX251 is currently in Phase 1 clinical development, where it is being evaluated for its pharmacokinetics, safety, and tolerability in patients with clinically stable schizophrenia.
- Other names
- cariprazine long-acting injectable
02
Targets
HTR2A (Serotonin receptor 5-HT2A)DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on AX251.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AX251.